Skip to main content
Fig. 1 | Molecular Neurodegeneration

Fig. 1

From: A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model

Fig. 1

PK and pharmacodynamic profiling of 51657. a Plasma and brain levels of 51657 (structure inset) after a 5 mg/kg i.p. dose. Brain levels exceed plasma levels at all times, with terminal plasma and brain T1/2 values of 1–1.5 h. Error bars represent SEM, with n = 3 per time point. b Levels of brain AcTub in WT mice 3 days after the last dose of vehicle or 10 mg/kg of 51657. Error bars represent SEM of n = 3 per treatment, with an unpaired t-test used to determine significance of compound effect

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326